40 recruiting, 27 completed, 13 terminated, 11 active not recruiting. 55 Phase 1, 44 Phase 2, 12 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow this condition Literature Review of Ewing Sarcoma trials Research Report on Ewing Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Immunotherapy Targeting Sarcomas Multiple sarcoma-specific CAR-T cells and sarcoma vaccines - Sarcoma, Osteoid Sarcoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-07-01 | 2026-08-26 |
| Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas Sarcoma-specific CAR-T cells - Sarcoma, Osteoid Sarcoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-06-01 | 2026-08-26 |
| RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT LX-101 - Ewing Sarcoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 120 | 2027-02-01 | 2026-08-24 |
| EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT EWSR1 immunotherapy, Pembrolizumab - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | Phase 1 | Not yet recruiting | Rabi Hanna | 24 | 2026-10-01 | 2026-09-17 |
| my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults my.naviGATE Digital Tool - Sarcoma, Osteosarcoma | Not applicable | Not yet recruiting | Dana-Farber Cancer Institute | 143 | 2026-08-20 | 2026-04-08 |
| Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma Proton Therapy (Adaptive) - Pediatric Solid Tumors, Rhabdomyosarcoma | Not applicable | Recruiting | St. Jude Children's Research Hospital | 100 | 2026-08-20 | 2026-08-21 |
| Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Eflornithine, Topotecan, Cyclophosphamide - Osteosarcoma, Ewing Sarcoma | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 406 | 2026-06-05 | 2026-10-06 |
| Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma Ewing Sarcoma, Bone Neoplasms | Not yet recruiting | Peking University People's Hospital | 55 | 2026-06-01 | 2026-06-02 | |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Eflornithine (DFMO), AMXT 1501 Dicaprate - Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 265 | 2026-05-13 | 2026-09-03 |
| Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors Methionine-Reduced Diet - Adenocarcinoma, Basal Cell Carcinoma | Early Phase 1 | Recruiting | University of California, Irvine | 25 | 2026-05-01 | 2026-07-31 |
| Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) Xaluritamig - Ewing Sarcoma | Phase 1 | Recruiting | Amgen | 50 | 2026-04-08 | 2026-09-25 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells - Rhabdomyosarcoma, Ewing Sarcoma | Phase 1 | Recruiting | Children's National Research Institute | 18 | 2026-01-27 | 2026-08-13 |
| Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas Fludarabine, Cyclophosphamide, B7-H3-CAR T Cells - Sarcoma, Childhood Osteosarcoma | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 42 | 2026-01-21 | 2026-02-09 |
| Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial Biospecimen Collection, Chemotherapy, Computed Tomography - Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion | Not applicable | Recruiting | Mayo Clinic | 170 | 2025-12-05 | 2026-10-06 |
| A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies ST-01156 - Advanced Solid Tumors, Ewing Sarcoma | Phase 1 | Recruiting | SEED Therapeutics, Inc. | 171 | 2025-12-01 | 2026-06-02 |
| Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma Ewing Sarcoma | Recruiting | Peking University People's Hospital | 100 | 2025-09-01 | 2026-07-24 | |
| A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors DXC008 - Prostate Cancer, Other Solid Tumors | Phase 1 | Recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 110 | 2025-05-15 | 2026-09-23 |
| Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma irinotecan liposome (II) + temozolomide + fluzoparib - Ewing Sarcoma | Phase 2 | Recruiting | Sun Yat-sen University | 29 | 2025-04-15 | 2025-05-31 |
| Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma Consolidative radiation therapy (cRT) - Metastatic Sarcoma, Radiation Therapy Patient | Not applicable | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 70 | 2025-03-25 | 2026-07-13 |
Showing 20 of 111. Sign in to see all of them.
Sarcoma, Ewing (111) · Osteosarcoma (49) · Sarcoma (47) · Rhabdomyosarcoma (44) · Neuroblastoma (34) · Wilms Tumor (21) · Bone Neoplasms (12) · Neoplasms (12) · Rhabdoid Tumor (12) · Neoplasms, Germ Cell and Embryonal (11) · Desmoplastic Small Round Cell Tumor (10) · Lymphoma (10) · Recurrence (10) · Melanoma (9) · Carcinoma, Hepatocellular (8)
Neoplasms by Histologic Type (110) · Neoplasms, Bone Tissue (110) · Neoplasms, Connective Tissue (110) · Neoplasms, Connective and Soft Tissue (110) · Neoplasms (99) · Sarcoma (64) · Osteosarcoma (62) · Neoplasms by Site (48) · Neoplasms, Muscle Tissue (47) · Neoplasms, Glandular and Epithelial (46) · Myosarcoma (44) · Neoplasms, Nerve Tissue (44) · Neuroectodermal Tumors (43) · Neoplasms, Neuroepithelial (39) · Neoplasms, Germ Cell and Embryonal (35)
Temozolomide (9) · Irinotecan (8) · Cyclophosphamide (7) · Topotecan (5) · Busulfan (3) · Drug Therapy (3) · Gemcitabine (3) · Melphalan (3) · Nivolumab (3) · Vincristine (3) · cabozantinib (3) · fludarabine (3) · Bone Marrow Transplantation (2) · Doxorubicin (2) · Eflornithine (2)
St. Jude Children's Research Hospital (6) · Peking University People's Hospital (5) · Dana-Farber Cancer Institute (4) · Istituto Ortopedico Rizzoli (4) · National Cancer Institute (NCI) (4) · Children's National Research Institute (3) · Milton S. Hershey Medical Center (3) · AeRang Kim (2) · Children's Hospital of Philadelphia (2) · Children's Oncology Group (2) · Eisai Inc. (2) · Gradalis, Inc. (2) · Pfizer (2) · Salarius Pharmaceuticals, LLC (2) · Sarcoma Alliance for Research through Collaboration (2)
United States (75) · China (12) · Italy (11) · France (10) · Australia (7) · Canada (7) · United Kingdom (7) · Spain (6) · Germany (5) · Netherlands (4) · Poland (3) · South Korea (3) · Sweden (3) · Belgium (2) · Brazil (2)
AeRang Kim, MD, PhD (4) · Alessandra Longhi, MD (2) · Brigitte C Widemann, M.D. (2) · John Nemunaitis, MD (2) · Theodore Laetsch, MD (2) · Aaron Enke (1) · AeRang Kim (1) · Aerang Kim, M.D. (1) · Alok Kothari, M.D. (1) · Amy Hont, MD (1) · Anna Pawlowska, MD (1) · Anna Raciborska, Prof. (1) · Asmaa Ellaithy, MD (1)
PMID 31401903, PMID 24089446, PMID 24711551, PMID 25838377, PMID 26331920, PMID 27974040, PMID 28735378, PMID 28934351, PMID 29558948, PMID 29977059, PMID 31902458, PMID 32169872, PMID 32471029, PMID 32733795, PMID 33289920, PMID 33305087, PMID 33572900, PMID 33844437, PMID 34772439, PMID 34885651, PMID 3497548, PMID 35327550, PMID 35681553, PMID 35880942, PMID 37018492, PMID 37018497, PMID 37265425, PMID 37306107, PMID 38070906, PMID 38873934, PMID 39122389, PMID 39255444, PMID 40841488, PMID 41991689
2023 (2), U10CA098543 (2), U10CA180886 (2), 2015 (1), 2016 (1), 2017 (1), P30CA060553 (1), R01CA276684 (1), U01CA142565 (1), U01CA236220 (1)